{
    "cancer_info": {
        "cancer_name": "Head and Neck Cancers"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "Complete head/neck physical exam (including mirror/fiberoptic laryngoscopy)",
            "Tobacco/alcohol history documentation",
            "Depression screening",
            "Contrast-enhanced CT of primary tumor and neck",
            "Contrast-enhanced MRI of primary tumor and neck",
            "FDG PET/CT for advanced staging/metastatic screening",
            "Chest CT with/without contrast",
            "Bone scan (if PET/CT unavailable)",
            "Panorex/dental CT for oral cavity",
            "Primary site biopsy",
            "Image-guided FNA/core biopsy (for genomic testing)",
            "Sentinel lymph node biopsy (SLNB) for oral cavity T1-T2 N0",
            "HPV testing (p16 IHC for oropharynx)",
            "EBV DNA testing (for nasopharyngeal carcinoma)",
            "Hepatitis B screening",
            "Dental/prosthodontic evaluation",
            "Nutrition assessment",
            "Speech/swallowing evaluation",
            "Audiogram",
            "Exam under anesthesia (EUA) with endoscopy",
            "Multidisciplinary team consultation",
            "Brain MRI (for mucosal melanoma/neurologic symptoms)",
            "Plasma EBV DNA monitoring (nasopharynx)",
            "NGS profiling for salivary tumors (AR, HER2, NTRK, RAS, PI3KCA, FGFR, BRAF, RET, MSI/dMMR, TMB, PD-L1)",
            "HMB-45/S100/Melan-A staining (mucosal melanoma)"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Early stage (T1-T2 N0)",
            "risk_group": "Low risk",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Oral cavity/oropharynx/larynx",
                    "plan_name": "Single modality",
                    "plan_details": "Surgical resection or definitive radiotherapy (60-70 Gy)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Glottic larynx",
                    "plan_name": "Radiotherapy",
                    "plan_details": "Accelerated RT (63 Gy/2.25 Gy/fx)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Locally advanced (T3-T4/N+)",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "treatment_line": "Definitive treatment",
                    "patient_subgroup": "Resectable disease",
                    "plan_name": "Surgery + adjuvant therapy",
                    "plan_details": "Resection + neck dissection → adjuvant RT ± concurrent cisplatin (60-66 Gy + cisplatin 100mg/m² q3w)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Definitive treatment",
                    "patient_subgroup": "Unresectable disease",
                    "plan_name": "Concurrent chemoradiation",
                    "plan_details": "Cisplatin 100mg/m² q3w + IMRT (70 Gy/7 wks)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Definitive treatment",
                    "patient_subgroup": "HPV+ oropharynx",
                    "plan_name": "De-escalated chemoradiation",
                    "plan_details": "Cisplatin + reduced-dose RT (50-60 Gy)",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Other recommended"
                },
                {
                    "treatment_line": "Definitive treatment",
                    "patient_subgroup": "Nasopharyngeal carcinoma",
                    "plan_name": "Concurrent cisplatin-RT",
                    "plan_details": "Cisplatin-based CRT (70 Gy) ± adjuvant chemo",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Metastatic/recurrent",
            "risk_group": "Systemic therapy candidates",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "PD-L1 CPS ≥1",
                    "plan_name": "Pembrolizumab-based therapy",
                    "plan_details": "Pembrolizumab ± platinum/5-FU",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Salivary duct carcinoma AR+",
                    "plan_name": "Androgen deprivation therapy",
                    "plan_details": "Leuprolide or abiraterone",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "EBV+ nasopharyngeal carcinoma",
                    "plan_name": "Gemcitabine-cisplatin ± toripalimab",
                    "plan_details": "Gemcitabine 1000mg/m² + cisplatin 80mg/m² ± toripalimab 240mg q3w",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Second-line treatment",
                    "patient_subgroup": "Platinum-refractory",
                    "plan_name": "Immunotherapy",
                    "plan_details": "Nivolumab or pembrolizumab",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Postoperative",
            "risk_group": "High-risk features",
            "treatment_plans": [
                {
                    "treatment_line": "Adjuvant therapy",
                    "patient_subgroup": "ENE/positive margins",
                    "plan_name": "Chemoradiation",
                    "plan_details": "Cisplatin 100mg/m² q3w + RT (60-66 Gy)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Adjuvant therapy",
                    "patient_subgroup": "Mucosal melanoma",
                    "plan_name": "Radiotherapy",
                    "plan_details": "IMRT (60-66 Gy) for close margins/PNI/LVI",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other recommended"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": [
            "HPV/p16 status: Defines prognosis in oropharyngeal cancer (HPV+ favorable) and guides treatment de-escalation",
            "EBV DNA: Prognostic marker in nasopharyngeal carcinoma; plasma levels correlate with tumor burden and recurrence risk",
            "PD-L1 CPS: Predicts response to immunotherapy (pembrolizumab/nivolumab); CPS≥1 required for 1L pembrolizumab monotherapy",
            "Extranodal extension (ENE): Adverse prognostic factor requiring intensified adjuvant therapy",
            "AR expression: Predicts response to androgen deprivation therapy in salivary duct carcinoma",
            "HER2 overexpression: Predicts response to trastuzumab/T-DXd in salivary gland tumors",
            "NTRK/RET fusions: Predict response to TRK/RET inhibitors across tumor types",
            "TMB-H/MSI-H/dMMR: Predict response to immunotherapy regardless of tumor origin",
            "Depth of invasion (DOI): Critical for T-staging in oral cancer and neck management decisions"
        ]
    },
    "guideline_id": "（2025.V1）NCCN临床实践指南：头颈部肿瘤.txt"
}